Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma
Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma
About this item
Full title
Author / Creator
Mateos, María-Victoria , Hernández, Miguel-Teodoro , Giraldo, Pilar , de la Rubia, Javier , de Arriba, Felipe , Corral, Lucía López , Rosiñol, Laura , Paiva, Bruno , Palomera, Luis , Bargay, Joan , Oriol, Albert , Prosper, Felipe , López, Javier , Olavarría, Eduardo , Quintana, Nuria , García, José-Luis , Bladé, Joan , Lahuerta, Juan-José and San Miguel, Jesús-F
Publisher
Waltham, MA: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
Waltham, MA: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
Certain clinical features predict progression from smoldering to overt multiple myeloma. Patients with high-risk features who were treated with lenalidomide and dexamethasone were less likely to have disease progression and had a higher rate of survival than untreated patients.
Smoldering multiple myeloma is a plasma-cell proliferative disorder...
Alternative Titles
Full title
Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma
Authors, Artists and Contributors
Author / Creator
Hernández, Miguel-Teodoro
Giraldo, Pilar
de la Rubia, Javier
de Arriba, Felipe
Corral, Lucía López
Rosiñol, Laura
Paiva, Bruno
Palomera, Luis
Bargay, Joan
Oriol, Albert
Prosper, Felipe
López, Javier
Olavarría, Eduardo
Quintana, Nuria
García, José-Luis
Bladé, Joan
Lahuerta, Juan-José
San Miguel, Jesús-F
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_1416937617
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_1416937617
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa1300439
